Senseonics Announces Equity Grants To Employees Under Inducement Plan
06 October 2022 - 11:00PM
Business Wire
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the design and manufacturing of
long-term, implantable continuous glucose monitoring (CGM) systems
for people with diabetes, today announced plans to participate in
the upcoming Morgan Stanley Global Healthcare Conference in New
York, NY.
On October 5, 2022, Senseonics Compensation Committee granted 6
new non-executive employees non-qualified stock options to purchase
an aggregate of 78,000 shares of the Company’s common stock as an
inducement for such employees to join the Company. The options have
an exercise price of $1.34 per share, which was the closing price
of the Company’s common stock on the NYSE American on October 5,
2022. In each case, 25% of the shares underlying the options will
vest on the first anniversary of the employee’s start date, with
the remainder vesting in monthly installments over the subsequent
three year period, in all cases contingent on such employee’s
continued service with the Company at the applicable vesting date.
Senseonics continues to work to bring its Eversense CGM System to
more people with diabetes in the U.S. and other markets around the
globe and drives to develop enhancements to the system.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 6 months. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration twice per day, and
when symptoms do not match CGM information or when taking
medications of the tetracycline class. The sensor insertion and
removal procedures are performed by a trained and certified health
care provider. The Eversense CGM System is a prescription device;
patients should talk to their health care provider to learn more.
For important safety information, see
https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, (“Senseonics”) is a medical technology
company focused on the development and manufacturing of glucose
monitoring products designed to transform lives in the global
diabetes community with differentiated, long-term implantable
glucose management technology. Senseonics' CGM systems, Eversense®,
Eversense® XL and Eversense® E3 include a small sensor inserted
completely under the skin that communicates with a smart
transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221006005396/en/
Senseonics Investor Contact Philip Taylor Investor
Relations 415-937-5406 investors@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From May 2023 to May 2024